FY2026 EPS Forecast for Korro Bio Increased by Analyst

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Korro Bio to a loss of $4.26 per share from a projected loss of $4.88, maintaining a Buy rating and $15 price target. Analysts’ average rating is Moderate Buy, with an average target of $16.50.
• Korro Bio reported a quarterly loss of $0.98 per share, beating the consensus estimate of a $1.14 loss by $0.16.

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Equities researchers at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of Korro Bio in a research note issued on Friday, November 6th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($4.26) for the year, up from their previous forecast of ($4.88). HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($4.92) per share. HC Wainwright also issued estimates for Korro Bio's Q4 2026 earnings at ($0.73) EPS, Q3 2027 earnings at ($1.25) EPS and FY2027 earnings at ($5.03) EPS.

KRRO has been the subject of a number of other research reports. Jefferies Financial Group set a $15.00 price target on Korro Bio in a research report on Tuesday, October 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Korro Bio in a research report on Friday, October 2nd. Finally, Wall Street Zen raised shares of Korro Bio from a "sell" rating to a "hold" rating in a research note on Saturday. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.50.

Korro Bio Stock Performance

KRRO opened at $14.96 on Tuesday. The business's fifty day moving average is $11.66 and its two-hundred day moving average is $12.08. The company has a market cap of $220.36 million, a price-to-earnings ratio of -1.65 and a beta of 3.23. Korro Bio has a one year low of $5.20 and a one year high of $36.79.

Korro Bio (NASDAQ:KRRO - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.16.

Institutional Investors Weigh In On Korro Bio

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Korro Bio during the second quarter worth about $10,776,000. Affinity Asset Advisors LLC acquired a new stake in Korro Bio during the first quarter worth approximately $8,002,000. Nantahala Capital Management LLC acquired a new stake in Korro Bio during the second quarter worth approximately $8,699,274. ADAR1 Capital Management LLC acquired a new stake in Korro Bio during the second quarter worth approximately $7,118,000. Finally, Kalehua Capital Management LLC purchased a new stake in Korro Bio in the 1st quarter worth approximately $1,238,000. 13.18% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Korro Bio news, Director Jean Formela sold 28,468 shares of the firm's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $14.00, for a total transaction of $398,552.00. Following the completion of the transaction, the director owned 141,053 shares of the company's stock, valued at approximately $1,974,742. This trade represents a 16.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Oliver Dolan sold 7,347 shares of the business's stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $13.51, for a total value of $99,257.97. Following the completion of the transaction, the senior vice president directly owned 16,252 shares of the company's stock, valued at approximately $219,564.52. This trade represents a 31.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders purchased 79,809 shares of company stock valued at $884,919 and sold 36,126 shares valued at $502,148. 4.80% of the stock is currently owned by company insiders.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company developing RNA editing medicines for genetically driven diseases. The company's approach is designed to make targeted changes to messenger RNA, potentially correcting or altering disease-related genetic instructions without permanently changing a patient's DNA.

Korro Bio's technology platform uses programmable oligonucleotides to guide RNA editing in specific cells and tissues. Its lead development program, KRRO-110, is being developed for alpha-1 antitrypsin deficiency, an inherited disorder caused by mutations in the SERPINA1 gene that can lead to liver and lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.